Ken Griffin Ac Immune Sa Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Ac Immune Sa stock. As of the latest transaction made, Citadel Advisors LLC holds 4,800 shares of ACIU stock, worth $7,920. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,800

Previous 7,600 36.84%

Holding current value

$7,920

Previous $20,000 60.0%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$1.87 - $2.98 $268,528 - $427,922	143,598 Added 1826.25%	151,461 $283,000
Q4 2024 Feb 14, 2025	SELL	$2.67 - $3.75 $37,227 - $52,286	-13,943 Reduced 63.94%	7,863 $21,000
Q3 2024 Nov 14, 2024	SELL	$2.99 - $4.2 $38,875 - $54,608	-13,002 Reduced 37.35%	21,806 $82,000
Q2 2024 Aug 14, 2024	SELL	$2.29 - $4.87 $59,365 - $126,249	-25,924 Reduced 42.69%	34,808 $138,000
Q1 2024 May 15, 2024	BUY	$2.66 - $4.87 $161,547 - $295,764	60,732 New	60,732 $179,000
Q3 2023 Nov 14, 2023	BUY	$2.77 - $3.38 $3,038 - $3,707	1,097 New	1,097 $3,000
Q1 2023 May 15, 2023	SELL	$2.13 - $2.49 $349,102 - $408,106	-163,898 Reduced 98.11%	3,165 $7,000
Q4 2022 Feb 14, 2023	BUY	$1.72 - $3.12 $287,348 - $521,236	167,063 New	167,063 $340,000
Q4 2021 Feb 14, 2022	SELL	$4.83 - $7.56 $50,362 - $78,828	-10,427 Reduced 28.93%	25,613 $126,000
Q3 2021 Nov 15, 2021	BUY	$6.2 - $8.34 $88,492 - $119,036	14,273 Added 65.57%	36,040 $242,000
Q2 2021 Aug 16, 2021	SELL	$6.04 - $8.37 $90,763 - $125,775	-15,027 Reduced 40.84%	21,767 $172,000
Q1 2021 May 17, 2021	BUY	$5.32 - $8.96 $68,223 - $114,903	12,824 Added 53.5%	36,794 $280,000
Q3 2020 Nov 16, 2020	BUY	$4.78 - $9.06 $114,576 - $217,168	23,970 New	23,970 $117,000
Q2 2020 Aug 14, 2020	SELL	$6.57 - $8.3 $282,155 - $356,451	-42,946 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$4.24 - $9.89 $166,301 - $387,905	-39,222 Reduced 47.73%	42,946 $297,000
Q4 2019 Feb 14, 2020	SELL	$4.56 - $8.78 $174,050 - $335,123	-38,169 Reduced 31.72%	82,168 $700,000
Q3 2019 Nov 14, 2019	SELL	$4.8 - $5.89 $221,232 - $271,470	-46,090 Reduced 27.69%	120,337 $595,000
Q2 2019 Aug 14, 2019	BUY	$4.72 - $5.88 $200,194 - $249,394	42,414 Added 34.2%	166,427 $924,000
Q1 2019 May 15, 2019	SELL	$3.65 - $11.68 $1.19 Million - $3.8 Million	-325,525 Reduced 72.41%	124,013 $0
Q4 2018 Feb 14, 2019	BUY	$7.35 - $11.7 $1.21 Million - $1.93 Million	164,701 Added 57.82%	449,538 $4.25 Million
Q3 2018 Nov 13, 2018	BUY	$7.88 - $16.45 $2.12 Million - $4.43 Million	269,094 Added 1709.29%	284,837 $0
Q1 2018 May 11, 2018	SELL	$10.34 - $13.78 $639,518 - $852,279	-61,849 Reduced 79.71%	15,743 $163,000
Q3 2017 Nov 09, 2017	BUY	$7.06 - $11.2 $547,799 - $869,030	77,592	77,592 $877,000

Others Institutions Holding ACIU

# of Institutions

Shares Held

27.2M

Call Options Held

4.8K

Put Options Held

22.2K

View Full List

About AC Immune SA

Ticker ACIU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,413,504
Market Cap $138M
Description
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectiv...

More about ACIU

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account